Study of the ITK Inhibitor Soquelitinib to Reduce Lymphoproliferation and Improve Cytopenias in Autoimmune Lymphoproliferative Syndrome (ALPS)-FAS Patients

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 10, 2025

Primary Completion Date

March 1, 2026

Study Completion Date

December 1, 2026

Conditions

Autoimmune Lymphoproliferative Syndrome

Interventions

DRUG

Soquelitinib

Soquelitinib is an ITK inhibitor in clinical development for treating relapsed/refractory T-cell lymphoma.

Trial Locations (3)

RECRUITING

The Children's Hospital of Philadelphia, Philadelphia

RECRUITING

National Institutes of Health Clinical Center, Bethesda

RECRUITING

Texas Children's Hospital, Houston

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH